## ISRG: Intuitive Surgical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.6% below STRENGTH zone (3.0-6.0%); PEG 3.46 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($553.46)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Intuitive Surgical Earnings Preview: What to Expect**
- Source: Palmetto Grain Brokerage | 20251223T100808 | Somewhat-Bullish | Relevance: 100%
- Intuitive Surgical, a leader in robotic-assisted surgery, is expected to announce its fiscal Q4 2025 results soon, with analysts predicting an EPS of $1.83. Despite lagging behind the S&P 500 and Health Care Select Sector SPDR Fund in stock performance, and a recent downgrade from Citigroup, analysts maintain a "Moderate Buy" rating with a target price implying a 5.9% upside.

**2. Baird Reaffirms Buy on Intuitive Surgical (ISRG) After New FDA Clearances**
- Source: Insider Monkey | 20251222T150840 | Bullish | Relevance: 100%
- Baird reaffirmed a Buy rating on Intuitive Surgical (ISRG) with a $655 price target, following the FDA's clearance of the da Vinci Single Port (SP) surgical system for three new procedures: inguinal hernia repair, cholecystectomy, and appendectomy. This expands the system's US indications, which already included urology and colorectal surgeries. The da Vinci SP enables complex operations through a single incision, and the company offers various instruments and services supporting these robotic systems globally.

**3. Baird Reaffirms Buy on Intuitive Surgical (ISRG) After New FDA Clearances**
- Source: Finviz | 20251222T150811 | Bullish | Relevance: 100%
- Baird has reaffirmed a Buy rating on Intuitive Surgical (ISRG) and maintained its $655 price target following new FDA clearances for its da Vinci Single Port (SP) surgical system. These clearances expand the system's indications to include inguinal hernia repair, cholecystectomy, and appendectomy, broadening its use beyond prior approvals. The da Vinci SP system allows surgeons to perform complex procedures through a single incision, with existing approvals in Europe, Japan, and Korea for a wider array of procedures.

**4. Intuitive Surgical Stock (ISRG) Week Ahead: FDA da Vinci 5 Recall Posting, da Vinci SP Expansion, and Fresh Wall Street Targets Into the Christmas Trading Week**
- Source: ts2.tech | 20251222T002510 | Neutral | Relevance: 100%
- Intuitive Surgical (ISRG) faces a holiday-shortened trading week with key developments: an FDA Class 2 recall on a da Vinci 5 component and expanded FDA clearance for da Vinci SP for three high-volume general surgery procedures. Analysts maintain a "Moderate Buy" consensus with price targets averaging $611.08, while investors will closely watch for any further commentary on the recall and how ISRG trades around its technical levels in a low-liquidity environment.

**5. Truist and RBC Capital Raise Price Targets on Intuitive Surgical (ISRG)**
- Source: Finviz | 20251221T145721 | Bullish | Relevance: 100%
- Truist and RBC Capital have both raised their price targets for Intuitive Surgical (ISRG) to $650, maintaining Buy and Outperform ratings, respectively. This positive outlook is driven by anticipated strong sector fundamentals in MedTech for 2026, supported by aging populations, improved healthcare access, and innovation. Intuitive Surgical's da Vinci 5 system has received positive feedback for its enhanced precision and efficiency.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $650 | $620 | +5% |
| 2025-12-17 | RBC Capital | $650 | $625 | +4% |
| 2025-12-11 | Citigroup | $635 | $650 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Buy |
| 2025-12-17 | RBC Capital | main | Outperform |
| 2025-12-11 | Citigroup | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 5 ($2.98M) |
| Sells | 13 ($5.48M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 35.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.8%)
- Blackrock Inc.: 8.8% (+0.1%)
- State Street Corpora: 4.3% (-0.1%)
- Price (T.Rowe) Assoc: 3.6% (-4.4%)
- Geode Capital Manage: 2.3% (+1.0%)

### Key Risks

1. Insider selling cluster: $5.5M in recent transactions.
2. Valuation stretched: PEG 3.5x requires aggressive growth execution.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.46 signals overvaluation risk, limited margin of safety. Forward P/E 59.2x stretched relative to 13% growth. Quality metrics strong (margin 29%). Balance sheet: strong liquidity (4.7x), low leverage (D/E 0.14). Institutional flow bearish (4 selling vs 5 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $207.0B |
| Beta | 1.69 |
| 52W Range | $425.00 - $616.00 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.46 |
| Forward P/E | 59.2 |
| Current P/E | 66.8 |
| YoY Growth | 12.8% |
| EPS Direction | RISING |

### Technicals

MRS_10 weakening modestly (-0.9% over 5 days). Below STRENGTH zone by 1.4pp (needs >3.0% for momentum thesis). MRS_5 (-0.2%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.62% (CS: 90) | Neutral |
| RSI_14 | 60.8 | Neutral |
| MACD Histogram | 0.13 | Bullish |
| vs SMA20 | 1.021x | Above |
| vs SMA50 | 1.060x | Above |
| vs SMA200 | 1.135x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $577.34
- **Stop Loss:** $553.46 (4.1% risk)
- **Target:** $601.22 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 50
- **Position Value:** $28,867.00
- **Portfolio %:** 28.87%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-01-22 (Est: $2.24)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.99 | $2.40 | +20.7% |
| 2025Q2 | $1.92 | $2.19 | +14.1% |
| 2025Q1 | $1.73 | $1.81 | +4.4% |
| 2024Q4 | $1.79 | $2.21 | +23.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*